Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HMPL-309
Theliatinib · 1 trial · 1 indication
for each patient, adverse events are collected from the date of consent until 30 days after trial discontinuation
| Arm | Type | Description |
|---|---|---|
| Theliatinib | EXPERIMENTAL | Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 5 dose cohorts,including120mg/160mg/200mg/220mg/300mg, QD in the dose escalation stage . |
| Name | Type | Description |
|---|---|---|
| Theliatinib | DRUG | Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily |
Inclusion Criteria: * Histopathology confirmed solid tumors * Failed to standard treatment or no standard treatments for uncontrolled, recurrent and/or metastatic advance tumor (whatever previous surgery conditions) * Age 18-75 * Performance status of 0, or 1, and no worse within 7days * Life expec...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Theliatinib is an investigational small molecule being studied for the treatment of cancer. It has been evaluated in patients with advanced solid tumors. It is not approved for any indication and remains in clinical development.
Theliatinib targets EGFR, the epidermal growth factor receptor. It is an EGFR inhibitor, meaning it is designed to block signaling through this receptor. EGFR is a commonly targeted pathway in oncology drug development.
Theliatinib is being developed by HUTCHMED (China) Limited, which trades under the ticker HCM. The company is the sponsor of the clinical program evaluating the drug in advanced solid tumors.
Theliatinib is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. The Phase 1 program has been completed.
Theliatinib has been studied in one clinical trial, NCT02601248, titled Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor. The Phase 1 trial enrolled 24 patients in China and is completed.
Yes, theliatinib is also known as HMPL-309. The two names refer to the same investigational EGFR inhibitor developed by HUTCHMED. The clinical trial listing for the drug uses both names.